Entrada hit with clinical hold on Duchenne drug
When Entrada Therapeutics unveiled its shiny new alliance with Vertex days ago surrounding myotonic dystrophy Type I, CEO Dipal Doshi took the opportunity to spotlight a separate program in Duchenne muscular dystrophy — which he was hoping to put into the clinic in 2023.
But a clinical hold from the FDA now threatens to delay those plans.
Entrada disclosed late Monday that it received a clinical hold notice regarding its program for ENTR-601-44, barring it from starting a single ascending dose study in healthy volunteers. Shares $TRDA plummeted 32% to $13.50.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.